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 ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not “Is 
regenerative injection therapy (prolotherapy) effective at reducing pain associated with knee 
osteoarthritis?” 
Study Design: Review of all English language primary studies published in 2012 and 2013. 
Data Sources: One randomized control trial, one randomized crossover study and one single-arm 
uncontrolled study were found using PubMed and Ebscohost. 
Outcomes Measured: Clinical outcome for all three articles was measured using the Western 
Ontario McMaster University Osteoarthritis Index (WOMAC); which specifically focuses on 
quality of life, function, and pain reduction after the use of prolotherapy versus the saline 
placebo. 
Results: In a randomized control study (RCT) by Rabago et al. (2012) they found that patients 
given prolotherapy sustained significant improvement of pain, function, and stiffness scores for 
knee osteoarthritis compared with the blinded saline injection group. The randomized crossover 
study by Dumais et al. also came to the conclusion that prolotherapy is associated with a marked 
reduction in symptoms that was sustained for over 24 weeks. The Rabago et al. (2013) single-
arm uncontrolled study also found similar results; 36% improvement on the WOMAC. 
Conclusions: Both randomized controlled trials and the single-arm uncontrolled studies included 
in this review indicate that regenerative injection therapy, also known as RIT or prolotherapy, is 
an effective treatment for knee osteoarthritis in regards to quality of life, pain, and function. 
Keywords: Prolotherapy, knee osteoarthritis, regenerative injection therapy 
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Introduction 
 Osteoarthritis is becoming extremely prevalent as the population is increasing in age and 
living longer. It is the most frequent form of arthritis in older adults; most commonly affecting 
the knees, hips, spine, and hands.
1  
Although joint replacement is the definitive treatment, 
patients and providers are searching for less invasive treatments to prolong quality of life, 
improve function, and relieve symptoms. This paper evaluates two randomized control studies 
and one single-arm uncontrolled study, looking at the effectiveness of intra-articular injections of 
dextrose mixed with lidocaine on function and pain in an osteoarthritic knee.  
 Osteoarthritis of the knee is one of the five leading causes of disability among non-
institutionalized adults.
1
 In the United States alone, osteoarthritis affects 13.9% of adults aged 25 
and older; 33.6% of those are adults over the age of 65 which amounts to roughly 12.4 million 
Americans.
  
In 2005, it was conservatively estimated that there were a total of 26.9 million 
Americans living with OA, which had significantly increased from 21 million in 1990.
1 
 
Everyday both physician assistants and physicians are working to treat their patients’ 
knee osteoarthritis, with the goal to improve their function and reduce pain. Although the exact 
number of visits for OA alone is not reported, the American Academy of Orthopaedic Surgeons 
stated that in 2004 healthcare visits by persons with arthritis or other rheumatic conditions 
included 44.2 million ambulatory care visits.  This represents 5% of all care visits to doctor’s 
offices, ERs, and outpatient clinics.
2
 According to the CDC in 2009 the costs due to hospital 
expenditures of total knee replacements amounted to $28.5 billion, with the total annual costs of 
OA per patient amounting to $5,700 per year.
1  
Nationally, the rate (per 100,000) of knee 
Aloi, Regeneration Injection Therapy, 2 
 
replacements has increased 187% from 1991 to 2007, which can be attributed to our growing 
older population.
1 
 
The specific causes of OA remain unknown, but is it believed to be a result of both 
mechanical and molecular events in the affected joint.  There are both modifiable and non-
modifiable risk factors for OA some of which include; excess body mass, joint injury, 
occupations that put more stress on the joints, gender, age, race, and genetic disposition.  The 
disease onset is gradual and usually begins after the age of 40. The etiology of pain and disability 
in knee OA is also not well understood but it is thought that the source of pain most likely 
includes the joint capsule, ligaments, synovium, bone, and the supportive extra-articular 
ligaments and tendons.
1
  
 The diagnosis of knee OA is a clinical diagnosis but the use of X-rays, MRI, and 
laboratory tests are often used to confirm or solidify the diagnosis. The criteria for OA of the 
knee include the presence of knee pain plus at least three of the following characteristics: Age 
>50, morning stiffness lasting less than 30 minutes, crepitus, bone tenderness of the knee, bony 
enlargement of the knee, and no detectable warmth of the joint to the touch.
3 
 There are multiple methods available to help treat osteoarthritis.  Some non-medical 
treatments used are weight loss, physical therapy, orthotics, assistive devices like canes or 
walkers, dietary supplements like glucosamine and chondroitin, or even the use of capsaicin 
cream. However, a key component to treating OA is drug therapy which include; NSAIDS, 
aspirin, glucocorticoid injections, and Hyaluronate injections.  The definitive treatment for OA is 
a total joint replacement, but this is usually reserved for severe OA or OA that is refractory to the 
less invasive methods.
3   
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When lifestyle modifications are not effective, and patients have tried all the medications 
but are not ready to have a joint replacement, practitioners look for other options to help the 
individual achieve the outcomes they want. Regenerative Injection therapy (Prolotherapy), is a 
current pharmacological treatment that may be an alternative beneficial treatment for knee OA 
that is noninvasive. Prolotherapy is an injection therapy currently used for chronic 
musculoskeletal injury in which small volumes of a hypertonic dextrose solution are injected into 
multiple painful areas over several treatment sessions. It is thought that it works by stimulating 
local healing. 
4 
Objective 
 The objective of this selective EBM review is to determine whether or not “Is 
regenerative injection therapy (Prolotherapy) effective at reducing pain associated with knee 
osteoarthritis?” 
Methods 
 This investigation looks at two randomized controlled trials and one single-arm crossover 
study.  In order to participate in the study the participants had to meet specific criteria which 
included the following; aged 18 and older or between the ages of 40 and 76, diagnosis of knee 
OA, diagnosed by a radiologist within 5 years of their enrollment, and moderate to severe knee 
pain for at least 3 months. All studies included regeneration injection therapy (RIT) of dextrose 
and lidocaine as the intervention therapy.  In the randomized controlled crossover study by 
Dumas et al. and the single-arm uncontrolled trial by Rabago et al. no comparison group was 
used.  In the RCT by Rabago et al. the groups being compared were RIT to a saline placebo and 
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exercise group. The main outcomes looked at for the purpose of this paper are function and pain 
reduction.  
 The author performed searches using the PubMed and Ebscohost databases using the key 
words of prolotherapy, regenerative injection therapy, and knee osteoarthritis.  All searches 
performed were set for English language.  All articles searched were published in peer-reviewed 
journals after the year 1999 and were selected based on relevance and importance of outcome to 
the patient. Inclusion criteria for the purpose of this paper included randomized controlled 
studies, cohort studies, and studies that included POEMs. Exclusion criteria included previous 
Cochrane reviews, and previous student published systematic reviews. All studies used similar 
statistics to evaluate the outcomes where p-value is considered statistically significant if it is less 
than or equal to 0.05. The demographics of the studies are included and outlined below in Table 
1.  
Table 1- Demographics and Characteristics of included studies 
Study Type 
# 
Pts 
Age 
(yrs) 
Inclusion 
criteria 
Exclusion 
Criteria 
W/D Intervention 
Dumais, 
2012 (1) 
RCT 
cross-
over 
45 18 and 
older 
Dx of knee 
OA, knee pain 
for min 6 mo, 
be able to 
understand and 
execute 
physio-therapy 
exercises, 18 
years and older 
Previous knee 
operation, 
abnormal 
coagulation, 
infection of skin 
surrounding 
knee, allergy to 
lidocaine, 
pregnancy or 
breast feeding 
9 Regenerative 
Inj Tx (RIT)- 
1cc 15% 
dextrose & 
0.6% lido-
caine in 8 
collateral 
ligaments, 5cc 
20% dextrose 
& 0.5% lido-
caine inside 
knee joint 
Rabago, 
2013 (2) 
RCT 98 40-76 Dx of knee 
OA, dx by 
radiologist 
w/in 5 yrs of 
Pregnancy, DM, 
anticoagulation 
tx, hx of TKR, 
prior knee prolo-
8 Intra-articular 
Inj of 5ml 
50% dextrose 
& 5mL lido-
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Outcomes Measured 
 All studies measured the outcomes using the Western Ontario McMaster University 
Osteoarthritis index (WOMAC), which specifically focuses on pain and functioning. 
Results 
 In the Rabago et al. RCT, 98 patients were used to compare RIT to a saline placebo and 
were recruited based on a set of inclusion/exclusion criteria provided in Table 1. The sample 
consisted of 66% women with a mean age of 56.7, 74% were either overweight or obese. 
Patients were randomly assigned to either a dextrose injection group or a saline injection group 
enrollment, 
tenderness of 
≥1 anterior 
knee structures 
on PE, self-
reported mod-
severe pain for 
≥3 months. 
therapy, post-
infectious knee 
arthritis, daily 
opioid use, 
allergy to study 
meds, BMI 
>40kg/m2,  
severe comor-
bidity preventing 
participation 
caine, 1% 
saline & 
extra-articular 
inj of 6.75 mL 
50% dextrose, 
4.5mL of 1% 
lidocaine. 
11.25mL 
0.9% saline 
Rabago, 
2012 (3) 
Single 
arm 
uncon-
trolled 
36 40-76 Dx of knee OA 
based on clin-
ical criteria, 
identification 
by a radiologist 
of knee OA on 
existing knee 
radiograph 
within 5 years, 
tenderness of 
one or more 
anterior knee 
structures on 
PE, and mod-
severe pain for 
≥3 mos prior. 
Pregnancy, sig-
nificant comor-
bidity, anticoag-
ulation tx, hx of 
or planned TKR, 
prolotherapy or 
other knee inj 
w/in past 3 mos, 
inflammatory or 
post-infx knee 
arthritis, daily 
opioid use, intol/ 
allergy to study 
meds, no  x-ray 
of affected knee, 
BMI >45kg.m2. 
2 Intra and 
extra-articular 
injections of 
25% dextrose 
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(this paper will not focus on the exercise group). The injections were performed at 1, 5, and 9 
weeks in an outpatient setting and injected intra- and extra-articularly according to a published 
protocol.  After the injections, participants were offered acetaminophen and eight 5mg 
oxycodone tablets to use as needed for up to 1 week and were advised to rest the knee for 2-3 
days following the injection. The primary outcome measured was the change in knee-related 
quality of life as assed by the composite score of WOMAC, a questionnaire evaluating OA 
severity using pain, stiffness, and function. The minimal clinical important difference on the 
WOMAC for knee OA has been reported as 12 points of change on a 0- to 100-mm visual analog 
scale. Secondary outcomes were measured using the knee pain scale (KPS). Data was analyzed 
using SAS 9.1 statistical software; and analysis was by intention-to-treat.  Percentage 
improvement in WOMAC scores was calculated as the change in total WOMAC scores from 
baseline to 52 weeks.
4
 A summary of results can be seen in Table 2. 
Table 2- WOMAC composite score change, Mean (SE) 
 Dextrose Saline P Value 
52 weeks 15.32 7.59 .022 
This study demonstrates that after 52 weeks participants who received the dextrose injection 
reported improved composite WOMAC scores, a 24% improvement (compared with baseline 
status) compared with those in the saline placebo group. The P value is .022 which is considered 
statistically significant. All injection group participants experienced mild to moderate post-
injection pain, 3 participants in the dextrose group and 5 in the saline group experienced self-
limiting bruising. There were no other side effects or adverse events noted. Overall, 91% of those 
in the dextrose group would recommend the treatment to other patients. 
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 In the Rabago et al. single-arm uncontrolled study 36 patients were included in the 
analysis of whom were recruited from outpatient clinics or former control groups.  The study 
consisted of Caucasian adults with an age range of 40-71, the majority were women with a BMI 
over 25 kg/m
2
. The remaining inclusion/exclusion criteria that participants needed to meet can be 
found in Table 1. There were 22 participants that had both knees treated, and 14 who only had a 
single knee injected totaling 58 total knees.  Prolotherapy injections (dextrose and lidocaine) 
were injected at 1, 5, and 9 weeks according to an existing protocol. Patients were offered 
acetaminophen and eight 5mg oxycodone tablets to use as needed for pain for up to 1 week post 
injection and advised to rest for the first 2 days.  The primary outcome measured was the change 
in knee-related quality of life as assed by the composite score of WOMAC.  The minimal clinical 
important difference on the WOMAC for knee OA has been reported as 12 points of change on a 
0- to 100-mm visual analog scale. Secondary outcomes were measured using the knee pain scale 
(KPS). Data was analyzed using SAS 9.1 statistical software; and analysis was by intention-to-
treat.  Percentage improvement in WOMAC scores was calculated as the change in total 
WOMAC scores from baseline to 52 weeks.
5
 A summary of results can be seen in Table 3. 
Table 3- total and change in WOMAC score 
 Dextrose P value 
52 weeks +15.9 <.001 
This study demonstrates that the WOMAC scores progressively improved from baseline to 52 
weeks; the p-value falling within the statistically significant range. The NNT to achieve minimal 
clinical importance difference of 12% was 2.  At the end of the 52 weeks, 38% of the participants 
achieved a 50% improvement in the total WOMAC score. 
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 In the study done by Dumais et al. they conducted a two-period crossover design in 
which the experiment was conducted over two consecutive time periods separated by a washout 
phase.  The patients included in this study had to have a diagnosis of knee OA, experience pain 
for a minimum of 6 months, be 18 years or older, and be able to execute the exercises. The 
exclusion criteria can be found in Table 1.  There were a total of 45 enrolled in the study. Group 
A was given home-based exercise program for 32 weeks in combination with RIT on weeks 0, 4, 
8, and 12.  Group B was also given the exercise program but had RIT on weeks 20, 24, 28, and 
32. The injections were placed using a pre-existing protocol. The primary outcome was assessed 
using the WOMAC.  For the first period, the changes were between week 16 and 0, and for the 
second period, the change between week 36 and 20 were compared using t-tests.
6
  The overall 
crossover design test results can be found in Table 4. 
Table 4- Overall Crossover design test 
 Est. Change RIT vs control 95% Cl P value 
WOMAC total -11.9 (-18.4, -5.5) <0.001 
As shown in the results, the use of RIT was associated with marked improvements in WOMAC 
scores.  The statistical analysis suggests that 29.5% of the improvement in WOMAC score can 
be attributed to RIT, which is considered statistically significant.  The RIT regimen was stopped 
in one participant in group B after reports of diffuse edema of both legs; however, no other 
adverse events were noted.  
Discussion 
These three articles showed that the use of RIT for knee OA has been effective in 
improving the overall quality of life, reducing pain, and increasing functioning. As this becomes 
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a more popular treatment for knee OA patients must consider the cost of having these injections 
done.  Since prolotherapy is relatively new in the medical field and still experimental, all 
insurance companies have yet to accept it as a cost-effective treatment.  Therefore, depending on 
one’s insurance, the injections may or may not be covered.  In instances where it is not covered, 
providers will oftentimes work with their patients on the payment. The exact price also depends 
on how many injections the patient needs, but one can expect it to cost between $150-$500 per 
session.
7 
Limitations of searching for studies were due to the fact that the use of prolotherapy is 
still very new and experimental. Its specific use in knee OA has not been studied to great extent 
thus far. A major limitation of these three studies was the small study size. The Dumais et al. 
study states that the limitations of their study were that it was not sufficiently powered for the 
secondary outcomes.  The analyses would have resulted in more secondary outcomes had there 
been a larger sample. In addition, another limitation of this study was that no placebo or saline 
injection control group existed. In the single-arm controlled study by Rabago et al. the 
limitations were the small sample size, and the assessment of participant satisfaction was indirect 
and subject to bias. Lastly, the RCT by Rabago et al. stated that the limitation in their study was 
also the small sample size which did not allow the detection of uncommon adverse events. 
Another limitation was the relative lack of participants with very severe baseline WOMAC 
scores. 
Conclusion 
 Although further studies are warranted, after reviewing these three studies evidence 
strongly suggests that regenerative injection therapy is effective at reducing pain associated with 
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knee osteoarthritis.
4,5,6
 The studies followed the participants for an appropriate amount of time 
and although the sample size was relatively small in each study, the results found were still 
considered statistically significant and in favor of RIT. However, all trials could have had larger 
sample sizes to provide stronger evidence that RIT is effective at reducing pain in knee OA. 
Future study is warranted to evaluate how many rounds of RIT are needed for substantial pain 
relief, and if there is a point at which patients become stagnant and do not improve. In addition, 
it would be beneficial to know how long the effects of RIT last; whether it needs to be repeated 
yearly or every 5 years etc.  
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